Biofrontera Inc. (BFRIW)
NasdaqCM: BFRIW
· Real-Time Price · USD
0.02
-0.01 (-33.33%)
At close: Aug 12, 2026, 3:28 PM
Biofrontera Inc. (BFRIW) Stock Price, Analysis & Data
-33.33% (1D)
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | 43.2M |
| Net Income (ttm) | -11.09M |
| Beta | 0.80 |
| EPS (ttm) | -1.3 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 0.05 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 768 |
| Avg. Volume (20D) | |
| Open | 0.10 |
| Previous Close | 0.03 |
| Day's Range | 0.02 - 0.03 |
| 52-Week Range | 0.02 - 0.03 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BFRIW
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts....
IPO Date Jul 17, 2026
Employees 84
Stock Exchange NasdaqCM
Ticker Symbol BFRIW
Website https://www.biofrontera-us.com
Financial Performance
In 2025, Biofrontera's revenue was 41.7M, an increase of 11.75% compared to the previous year's 37.32M. Earnings were -10.54M, a decrease of -40.67%.
Financial Statements
Page 1 of 2